



Contents available at ScienceDirect

Diabetes Research
and Clinical Practicejournal homepage: www.elsevier.com/locate/diabresInternational
Diabetes
Federation

Continuous glucose monitoring use and glucose variability in pre-school children with type 1 diabetes

Klemen Douc^{a,b}, Kevin Cargnelutti^c, Anze Sturm^d, Julij Selb^e, Natasa Bratina^a, Tadej Battelino^{a,d,*}

^a Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, University Medical Centre, Ljubljana, Slovenia

^b Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK

^c Faculty of Medicine and Surgery, University of Udine, Udine, Italy

^d Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

^e University Clinic of Respiratory and Allergic Diseases Golnik, Kranj, Slovenia

ARTICLE INFO

Article history:

Received 12 July 2018

Received in revised form

19 September 2018

Accepted 10 October 2018

Available online 15 October 2018

Keywords:

Continuous glucose monitoring

Type 1 Diabetes

Children

Insulin therapy

ABSTRACT

Aims: The objective of this nationwide population-based cohort study was to evaluate the correlation between continuous glucose monitoring (CGM) use and glucose variability in pre-schoolers with type 1 diabetes.

Methods: We analysed data from the Slovenian National Registry. The primary endpoint was the difference in glucose variability between periods, during which participants were using CGM and periods, during which CGM was not used, over 5 years.

Results: A total of 40 children <8 years old were followed for an estimated observational period of 116 patient/years. Mean age at CGM initiation was 3.5 (± 1.7) years. Both standard deviation of mean glucose [3.6 mmol/L (3.2–3.9) with CGM and 4.3 mmol/L (3.8–4.7) without CGM, $p < 0.001$] and coefficient of variation [44.0% (40.4–47.0) with CGM and 46.1% (42.3–49.4) without CGM, $p = 0.021$] were lower during the periods, when CGM was used. Frequent CGM use (>5 days/week) was associated with a 0.4% [4.4 mmol/mol] reduction in glycated haemoglobin level (7.6% compared to 7.2%, $p = 0.047$).

Conclusions: Our results indicate that the use of CGM was associated with reduced glucose variability during a 5 year follow-up period among pre-schoolers with type 1 diabetes.

Trial Registration: Clinicaltrials.gov: NCT-03293082.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Continuous glucose monitoring (CGM) has been repeatedly demonstrated to improve glycaemic control, both in adult

and paediatric populations [1], and is recommended as part of routine diabetes management [2]. However, in the youngest children, the benefit of CGM on glycated haemoglobin (HbA1c) has not been demonstrated [3]. Glycaemic variability (GV) is

* Corresponding author at: University Children's Hospital, Bohoričeva 20, 1000 Ljubljana, Slovenia.

E-mail address: tadej.battelino@mf.uni-lj.si (T. Battelino).

<https://doi.org/10.1016/j.diabres.2018.10.005>

0168-8227/© 2018 The Authors. Published by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

associated with a negative impact on brain volume and growth [4], and markers of cardiovascular morbidity [5] in children with type 1 diabetes, despite short disease duration. The use of CGM can reduce GV in adults and youth with type 1 diabetes [6,7], however, this has not yet been proven in pre-school children. To explore the impact of CGM use on GV in pre-school children with type 1 diabetes, we analysed data from a prospective national type 1 diabetes registry [8] during a 5 year follow-up.

2. Materials and methods

2.1. Study participants

Data on pre-school children with type 1 diabetes using continuous subcutaneous insulin infusion (CSII) therapy, who started using CGM before the age of seven (inclusive) years from 2012 until 2017 were searched from the Slovenian National Type 1 Diabetes Registry. To be included in the analysis, children had to have type 1 diabetes for at least 6 months prior to the observation start date, more than 3 months of CSII use, and at least one follow-up period with and one without CGM use. Only reports after the introduction of CGM therapy were included.

The study protocol was approved by the Slovene Medical Ethics Committee and conducted in line with the last revision of the Declaration of Helsinki with amendments. Patients gave their written informed consent for the anonymous use of data.

2.2. Study devices

All participants used the same real-time CGM brand (Enlite II sensor with MiniLinkREAL-Time transmitter; Medtronic Diabetes, Northridge, CA, USA) and CSII – either Minimed 640G system or Paradigm Veo (both Medtronic Diabetes, Northridge, CA, USA). CSII device infuses a rapid-acting human insulin analog to the subcutaneous tissue at programmed basal rates to mimic the individual's needs, with additional bolus doses to cover meals and correct hyperglycemia. This form of therapy is, based on international recommendations, becoming the insulin regimen of choice in many countries, particularly for young children with type 1 diabetes and for better comparability, we have included only children with type 1 diabetes using CSII [9,10].

2.3. Statistical analysis

The primary endpoint was the difference in GV, measured as standard deviation (SD) of mean glucose and coefficient of variation (CV) [11], between periods during which participants were using CGM, and periods during which CGM was not used (self-monitoring of blood glucose (SMBG) periods). When a participant had multiple CGM and/or multiple SMBG periods, median values of investigated variables during the CGM or SMBG periods were calculated.

The parameters between CGM and SMBG periods were compared using Wilcoxon signed-rank test. To further elucidate the impact of CGM usage, participants were divided into

frequent sensor users and non-frequent sensor users based on the threshold of using CGM for more than 5 days per week during the sensor period. These variables between frequent and non-frequent CGM users were compared with Mann-Whitney *U* test. To balance the effect of the outliers, we have used non-parametric statistical methods and we report the full range of values for each section. Statistical analysis was performed using R statistical language.

To account for the possible effect of a different number of times the glucose value was measured (glucose value in people with diabetes is non-normally distributed) with a sensor device and with SMBG on the standard deviation of glucose values, we simulated daily glucose variability of a person with type 1 diabetes, sampled from this simulation 10,000 times two samples with either 10 or 200 measurements, calculated standard deviation for each sample, and compared the standard deviations to each other. The mean standard deviation of samples with 10 measurements was significantly lower (*t*-test) from the mean standard deviation of samples with 200 measurements (data not shown).

3. Results

We identified 43 pre-school children (age < 8 years) with type 1 diabetes using CGM (mean (SD) age at diabetes onset 2.6 (± 1.3) years, at CSII initiation 2.8 (± 1.6) years, age at CGM initiation 3.5 (± 1.7) years, and mean duration of type 1 diabetes of 3.7 (± 1.8) years). Three participants were excluded due to lack of non-CGM periods data. Data from 40 participants were analysed. CGM data were available for 214 reports, and SMBG only (control) data for 250 reports, with an estimated observational period of 116 patient/years. On average, participants had 5.4 (± 4.4) CGM reports and 6.3 (± 4.6) non-CGM (SMBG only) reports, with a median (IQR) number of SMBG measurements of 7.1 (2.1) in CGM and 7.7 (1.8) in non-CGM ($p = 0.15$) per day.

Data representing glucose variability and glycaemic control are shown in Table 1 (median (IQR)) and Fig. 1. Both glucose SD and CV decreased with CGM use: SD was 3.6 mmol/L (3.2–3.9) with CGM, compared to 4.3 mmol/L (3.8–4.7) without CGM, $p < 0.001$; and CV was 44.0% (40.4–47.0) with CGM, compared to 46.1% (42.3–49.4) without CGM, $p = 0.021$.

There was no difference in CGM-measured mean glucose level (9.4 mmol/L) compared to SMBG mean glucose (9.3 mmol/L, $p = 0.189$), or HbA1c (7.6% (59.6 mmol/mol) with CGM and 7.7% (60.7 mmol/mol) with SMBG use, $p = 0.867$). The numerical difference in total daily insulin failed to reach statistical significance: 9.7 units per day (7.3–12.9) with CGM and 8.9 units per day (6.2–12.2, $p = 0.057$) with SMBG.

Frequent (>5 days/week, 12 participants) CGM use was associated with a reduction in HbA1c by 0.4% [4.4 mmol/mol]: 7.2% (6.8–7.6) [55.2 mmol/mol (50.8–59.6)] with frequent CGM use and 7.6% (7.4–8.0) [59.6 mmol/mol (57.4–63.9)] with non-frequent CGM use, $p = 0.047$.


Overall, there were no severe hypoglycaemic events in either group. Five participants (one in CGM group and four in SMBG group, estimated admission rate 4.3/100 patient-years) required hospitalization due to diabetic ketoacidosis that resolved with parenteral hydration and iv insulin infusion.

Table 1 – Glycaemic control comparing sensor-based glucose metrics to SMBG and frequent (>5 days/week) CGM to non-frequent CGM.

	CGM	SMBG only	p value
CV (%)	44.0 (40.4–47.0)	46.1 (42.3–49.4)	0.021
SD (mmol/L)	3.6 (3.2–3.9)	4.3 (3.8–4.7)	< 0.001
SD (mg/dL)	64.8 (57.6–70.2)	77.4 (68.4–84.6)	< 0.001
Mean glucose (mmol/L)	9.4 (8.7–10.2)	9.3 (7.9–10.1)	0.189
Mean glucose (mg/dl)	169.2 (156.6–183.6)	167.3 (142.2–181.8)	0.189
TDD (units/day)	9.7 (7.3–12.9)	8.9(6.2–12.2)	0.057
HbA1c (%)	7.6 (7.2–8.0)	7.7 (7.2–8.0)	0.867
HbA1c (mmol/mol)	59.6 (55.2–63.9)	60.7 (55.2–63.9)	0.867
	<i>Frequent CGM</i>	<i>Non-Frequent CGM</i>	
CV (%)	36.0 (34.0–37.0)	37 (35.0–39.0)	0.152
SD (mmol/L)	3.3 (3.1–3.7)	3.6 (3.3–3.9)	0.144
SD (mg/dL)	59.4 (55.8–66.6)	64.8 (59.4–70.2)	0.144
Mean glucose (mmol/L)	9.1 (8.6–9.8)	9.7 (8.9–10.1)	0.286
Mean glucose (mg/dl)	163.8 (154.8–176.4)	174.6 (160.2–181.8)	0.286
HbA1c (%)	7.2 (6.8–7.6)	7.6 (7.4–8.0)	0.047
HbA1c (mmol/mol)	55.2 (50.8–59.6)	59.6 (57.4–63.9)	0.047

Nonparametric analyses for data on glucose control (paired nonparametric Wilcoxon signed rank test), frequent/non-frequent CGM use (Mann–Whitney U test), and outcome data are presented as median (IQR), although variables for the analyses were mean (glucose, glucose concentration SD).

CGM – Continuous glucose monitoring, SMBG – Self-monitoring of blood glucose, TDD – Total daily dose

**Fig. 1 – A. Glycaemic control comparing A. CGM (purple) to non-CGM (green) periods and B. CGM frequent (>5 days/week) CGM (purple) to non-frequent CGM (green) periods. CGM – Continuous Glucose Monitoring. CV – Coefficient of variation of mean glucose. HbA1c – glycated Hemoglobin. SD – Standard deviation of mean glucose. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)**

4. Discussion

Increased availability and reimbursement of real-time CGM devices among paediatric patients has the potential to improve glycaemic control beyond HbA1c in this vulnerable population [12,13]. This study in pre-school children with type 1 diabetes demonstrated that CGM use can reduce glucose fluctuations compared to SMBG alone, hence improving glycaemic control beyond HbA1c in a real-life setting. Possible explanations include more frequent real-time insulin adjustments based on sensor glucose trends in this group of children, where parents are usually responsible for diabetes management. Similarly, data from the JDRF study of CGM use in type 1 diabetes, which included 142 children aged between 8 and 14 years, showed that after 26 weeks of CGM use almost all indices of GV declined compared to baseline [14].

The role of GV as a risk factor for developing complications of diabetes remains controversial, however, several reports associate GV with oxidative stress and damage to susceptible organs [15,16] and chromosomes [17]. Consequently, preventing excessive glucose fluctuations early in the disease course could provide long-term benefit for children. A recent call to action emphasized that not only diabetologists but also regulatory bodies should acknowledge therapies that improve time in range, glycaemic variability, and other parameters beyond HbA1c [18,19].

An appropriate incorporation of CGM data into clinical practice, both for day-to-day decision making and retrospective analysis, remains a challenge for children, their families, and professional health-care providers. Particularly as the CGM efficacy is associated with the frequency of its use: those who used near-daily CGM have a greater reduction in HbA1c and a greater percentage of blood glucose values in target range compared with those who use it less frequently [20]. Our data showed that frequent use of CGM for at least five days per week was associated with a significant decrease in HbA1c by 0.4% [4.4 mmol/mol].

Limitations of this analysis include the observational design and retrospective analysis, therefore, we could not control for confounding factors and observed associations cannot prove causality. Also, some of the recommended CGM and glycemic variability metrics (such as low and high blood glucose index, mean amplitude of glycemic excursions and others) could not be calculated. Reasons for CGM use discontinuation were not evaluated in this analysis. As some participants use CGM intermittently between non-CGM periods, there might be possible carry-over effect with the lack of any wash-out period. The difference in the number of glucose measurements per day with the CGM compared to SMBG can influence the standard deviation of mean glucose, however, in the direction opposite to the result in this study, as demonstrated by our *in silico* sampling. Because of these limitations, our reported observations should be interpreted with caution.

In summary, long-term CGM use reduced GV in pre-school children with type 1 diabetes. Our data support the use of CGM early in disease course in pre-school children, for whom we currently lack evidence-based treatment guidelines.

Prospective studies investigating potential benefits of CGM use in this subgroup of patients, particularly related to the developing brain, and implementing outcomes beyond HbA1c, are warranted.

Acknowledgements

The authors thank the staff from the Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital in Ljubljana. T.B. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

The study was funded in part by the University Medical Centre Ljubljana Research and Development Grant no.: 20110359, and Slovenian National Research Agency Grants no.: J3-6798, V3-1505 and P3-0343 without involvement from a commercial sponsor.

Duality of Interest

NB received honoraria for participation on the speaker's bureau of Medtronic and Roche. TB served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic and Bayer Health Care. TB's Institution received research grant support, with receipt of travel and accommodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz and Diamyd. KD, KC, JS and AS declare that there is no duality of interest associated with their contribution to this manuscript. No commercial company was involved in the planning, conduct, statistical analysis, results reporting and drafting of the manuscript.

Author Contributions

KD, KC, JS, AS, NB, and TB contributed to the study concept and design. NB and TB supervised the study. KD, KC, JS, and AS collected data. All authors participated in data analysis and interpretation. The manuscript was drafted by KD, NB and TB, and reviewed by KD, KC, JS, AS, NB, TB. All authors read and approved the final submitted version of the manuscript.

REFERENCES

- [1] Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. *Diabetes Technol Ther* 2017;19:S25–37.
- [2] Phillip M, Danne T, Shalitin S, Buckingham B, Laffel L, Tamborlane W, et al. Use of continuous glucose monitoring in children and adolescents (*). *Pediatr Diabetes* 2012;13:215–28.
- [3] Mauras N, Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, et al. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the

- management of type 1 diabetes in young children aged 4 to 10 years. *Diabetes Care* 2012;35:204–10.
- [4] Mazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, et al. Variations in brain volume and growth in young children with type 1 diabetes. *Diabetes* 2016;65:476–85.
- [5] Jamiolkowska M, Jamiolkowska I, Luczyński W, Totwińska J, Bossowski A, Głowińska Olszewska B. Impact of real-time continuous glucose monitoring use on glucose variability and endothelial function in adolescents with type 1 diabetes: new technology—new possibility to decrease cardiovascular risk? *J Diabetes Res* 2016;2016:1–8.
- [6] Buse JB, Kudva YC, Battelino T, Davis SN, Shin J, Welsh JB. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. *Diabetes Technol Ther* 2012;14:644–7.
- [7] Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. *Lancet* 2018;391:1367–77.
- [8] Dovc K, Telic SS, Lusa L, Bratanic N, Zerjav-Tansek M, Kotnik P, et al. Improved metabolic control in pediatric patients with type 1 diabetes: a nationwide prospective 12-year time trends analysis. *Diabetes Technol Ther* 2014;16:33–40.
- [9] Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European society for paediatric endocrinology, the lawson wilkins pediatric endocrine society, and the international society for pediatric and adolescent diabetes. *Diabetes Care* 2007;30(6):1653–62.
- [10] Sundberg F, Barnard K, Cato A, de Beaufort C, DiMeglio LA, Dooley G, et al. Managing diabetes in preschool children. *Pediatr Diabetes* 2017;18(7):499–517.
- [11] Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. *Diabetes Care* 2017;40:1631–40.
- [12] Forlenza GP, Pyle LL, Maahs DM, Dunn TC. Ambulatory glucose profile analysis of the juvenile diabetes research foundation continuous glucose monitoring dataset—applications to the pediatric diabetes population. *Pediatr Diabetes* 2017;1:622–8.
- [13] Heinemann L, Devries JH. Evidence for continuous glucose monitoring: sufficient for reimbursement? *Diabet Med* 2014;31:122–5.
- [14] El-Laboudi AH, Godsland IF, Johnston DG, Oliver NS. Measures of glycemic variability in type 1 diabetes and the effect of real-time continuous glucose monitoring. *Diabetes Technol Ther* 2016;18:806–12.
- [15] Hoffman RP, Dye AS, Huang H, Bauer JA. Glycemic variability predicts inflammation in adolescents with type 1 diabetes. *J Pediatr Endocrinol Metab* 2016;29:1129–33.
- [16] Akirov A, Diker-Cohen T, Masri-Iraqi H, Shimon I. High glucose variability increases mortality risk in hospitalized patients. *J Clin Endocrinol Metab* 2017;102:2230–41.
- [17] Tesovnik T, Kovac J, Hovnik T, Dovc K, Bratina N, Battelino T, et al. Association of glycemic control and cell stress with telomere attrition in type 1 diabetes. *JAMA Pediatr* 2018. <https://doi.org/10.1001/jamapediatrics.2018.1175> [Epub ahead of print].
- [18] Beyond A1C Writing Group BAW. Need for regulatory change to incorporate beyond A1C glycemic metrics. *Diabetes Care* 2018;41(6):e92–4.
- [19] Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American association of clinical endocrinologists, the American association of diabetes educators, the American diabetes association, the endo. *Diabetes Care* 2017;40(12):1622–30.
- [20] Wong JC, Foster NC, Maahs DM, Raghinaru D, Bergenstal RM, Ahmann AJ, et al. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. *Diabetes Care* 2014;37:2702–9.